Retatrutide vs. Tirzepatide: A Head-to-Head Obesity Trial

Obesity represents a significant global public health crisis, contributing to numerous comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. While several pharmacological interventions exist, including highly effective incretin-based therapies like Tirzepatide, there remains a need for comparative data to guide optimal treatment selection. This Phase 3 study directly addresses this knowledge gap by comparing the efficacy and safety of Retatrutide, a novel triple-agonist, against the established dual-agonist Tirzepatide in adults living with obesity.